Drawing for GRAFALON

USPTO serial 79414175

GRAFALON

Reviewed by CopyMark Law Group

Reg. 8163972Status 700Registered
Filing date
Status date
Registration date
Mar 10, 2026
Examiner
O'BRIEN, JENNIFER LYNN
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with GRAFALON?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Patrick F. Clunk

Patrick F. Clunk Tucker Ellis LLP950 Main Ave, Suite 1100Cleveland, OH 44113United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical compositions and preparations, namely, pharmaceutical preparations for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis, aplastic anemia, autoimmune diseases, diabetes, and for the prevention and treatment of graft-versus-host disease, hemophagocytic lymphohistiocytosis, lupus nephritis, multiple sclerosis, myelodysplastic syndrome, myelofibrosis, systemic lupus erythematosus, as well as for use in organ and tissue transplantation; biopharmaceutical compositions and preparations, in particular those for use in the treatment of immunological conditions, tissue, stem cell and organ transplants, tumors and immune system conditions; medicinal preparations for the treatment of infectious diseases and for use in oncology and hematology; medicinal preparations for use in stem cell transplant procedures; medicinal preparations for use in organ transplant procedures.ACTIVE—
042Scientific services and research for medical purposes, namely medical and scientific research in the field of cell biology and antibodies and immunology; scientific and technological services, namely scientific research, analysis, testing in the field of biotechnology, biopharmaceutics and medical science; biotechnological and biopharmaceutical analyses, namely blood analysis services for scientific research purpose, cell analysis services for scientific research purpose, DNA analysis services for scientific research purpose, human leukocyte antigen (HLA) analysis services for scientific research purpose , antibodies analysis services for scientific research purpose, antigen analysis services for scientific research purposes, Technical research in the field of pharmaceutical studies; medical research laboratory services.ACTIVE—
044Medical services; medical, pharmaceutical and biopharmaceutical services in the nature of medical and pharmaceutical consultation and medical advice and information in the field of oncology, hematology, stem cell transplantation, organ transplantation and immunological therapy.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 10, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 25, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 24, 2026FIMPFINAL DISPOSITION PROCESSED—
Jun 18, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jun 10, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 1, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
May 31, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Mar 10, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Mar 10, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 20, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 20, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 14, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 19, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 18, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Dec 18, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 18, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 18, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 24, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 24, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 24, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 8, 2025RFNTREFUSAL PROCESSED BY IB—
Jul 24, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 24, 2025RFRRREFUSAL PROCESSED BY MPU—
Jun 1, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 31, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 28, 2025DOCKASSIGNED TO EXAMINER—
Jan 11, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 11, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 2, 2025SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance